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Introduction {#S0001}
============

*p53* is an important protein in human biology. One of the major roles of p53 is that it regulates the cell cycle integrity ([@CIT0001]) therefore, functions as a tumor suppressor. *p53* prevents aberrant cell proliferation following diverse cellular stresses such as hypoxia, DNA damages, radiation, or chemotherapeutic drugs ([@CIT0002], [@CIT0003]) through regulation of expression of a number genes ([@CIT0004], [@CIT0005]), thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. For this reason, *p53* has been named as \"the guardian of the genome\" because of its role in conserving stability by preventing genome mutation.

Since its discovery in 1979, *p53* has been the focus of attention of scientist throughout the world. According to some reports, more than 50% of adult human tumors bear inactivating mutations or deletions in the *p53* gene ([@CIT0006]) which reflects its importance as a tumor suppressor gene. Therefore, disruption of its function(s) has a salient effect on the integrity of cell cycle and confers a selective advantage for tumor cells progression.

*p53* gene abnormalities appear to be key factors in the development of gastric cancer and can be observed at early stages of carcinogenesis such as gastritis and maybe subsequent genetic abnormalities enable these precancerous lesions to grow toward neoplasm and ultimately gastric cancer ([@CIT0007], [@CIT0008]). Also, these alterations can be used as a biomarker for early diagnosis and to determine prognosis of intermediate stages or even for risk assessment of cancer development.

There is limited information on the *p53* alterations in gastric cancer and its precancerous lesions from Iranian population ([@CIT0009], [@CIT0010]) while this population experiences one of the highest rate of incidence and mortality for gastric cancer in the world ([@CIT0011]). In addition, most of previous studies on gastritis were only limited to *p53* exon polymorphisms, and there is little work on the introns ([@CIT0012], [@CIT0013]), while the sequence environ SNPs can modulate its impact on the function and structure of the resultant protein. In line with this claim, the hypothesis that the genetic variation flanking codon 72 could affect *p53* function and characteristics is not new.

It is conceivable that some residues be collectively involved in the special functions of *p53*, not a single residue, for example, residues from 66-326 have a critical role in the *p53* degradation by E6 ([@CIT0014]). Also, there is some contrary regarding to which allele of codon 72 is a susceptibility marker for gastric cancer ([@CIT0015]), maybe these conflicting findings results from considering this codon itself or with different neighboring sequences in different studies. Therefore, evaluation of some polymorphisms together and determining their probable interaction may delineate some discrepancies.

There is no information about the probable correlation of exon and intron polymorphisms of *p53* especially in gastric cancer and its precancerous lesions. Therefore, it seems valuable to do a comprehensive study on the probable correlation between exon and intron polymorphisms of *p53* gene and their association with clinicopathological aspects.

Cells lacking *p53* exhibit a condition of genomic instability ([@CIT0016], [@CIT0017]). Therefore, *p53* function is necessary for genomic stability. Apparently *p53* has direct or indirect roles in the recognition of DNA damages and preserves genomic stability by regulating repair systems ([@CIT0018], [@CIT0019]) or cell death ([@CIT0020]). Therefore, examination of a marker for genomic stability status such as microsatellite status will be valuable. Microsatellite instability (MSI) is a genome-wide alteration characterized by some global instability of repetitive microsatellite sequences ([@CIT0021]). Hence, we decided to evaluate the probable correlation between exon and intron polymorphisms of *p53* gene and their correlation with MSI status to find additional insight about their potential effects on gastritis development and probable interplay among these processes during gastritis genesis.

Patients and Methods {#S0002}
====================

This study was approved by the ethics and scientific committee of *Gastroenterology and Liver Diseases Research Center*, Shahid Beheshti university of Medical Sciences. The patients were informed about the aims of this study and were empowered to participate in this study. During endoscopic examination, samples from gastritis lesion and normal endoscopic appearance were taken from the patients. The histological grading was performed according to the update Sydney classification. *H.pylori* (HP) infection was evaluated histologically. None of samples was immunohistochemically positive for *p53* protein ([@CIT0009]).

DNA extraction {#S20003}
--------------

The DNA from gastric biopsies was extracted using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions.

PCR amplification and mutation analysis using direct sequencing {#S20004}
---------------------------------------------------------------

To search for nucleotide alterations of the *p53* gene the primers were design to cover exon 2-7 and some intron region especially donor and acceptor splice sites. PCR-sequencing was done using primers ([Table 1](#T0001){ref-type="table"},) as follows:

###### 

Details of primers for PCR amplification for exons and introns of p53 gene.

                                  Primers                                Coverage[\*](#TF0001){ref-type="table-fn"}
  ------------------------------- -------------------------------------- --------------------------------------------
  Exon and intron 2&3             Forward:5' TCTCAGACACTGGCATGGTG 3'     12853-13319
                                  Reverse: 5' GGCAAGGGGGACTGTAGATG 3'    
  Exon and intron 4               Forward: 5\'CTAGCAGAGACCTGTGGGAAG 3'   13115-13702
                                  Reverse: 5' CACTGACAGGAAGCCAAAGG 3'    
  Exon 5 & 6 and intron 4, 5, 6   Forward: 5' TTGTTTCTTTGCTGCCGTC 3'     14259-14799
                                  Reverse: 5' CCCCCTACTGCTCACCTGG 3'     
  Exon 7 and intron 6, 7          Forward: 5\'GCGACAGAGCGAGATTCC 3'      15181-15588
                                  Reverse: 5\'CTGAGTGGGAGCAGTAAGGAG 3'   

Coverage column shows the site of primers attachment according to gene bank data (Accession number AY838896.1)

PCR was carried out in 25 µl of reaction containing 1x PCR buffer, 1.5 mM MgCl~2~, 10 pmol of each primer, 200 µM of each dNTP and half a unit Taq polymerase. The PCR conditions for each region were as follow: initial cycle of 5 min at 94°C and then 30 cycles of 30s at 94°C, 30s at 62.1°C for exon 2&3, 59.5 °C for exon 4, 63°C for exon 5&6, 62.1°C for exon 7, 45s at 72°C that was concluded by 10 min at 72°C. DNA Sequencing was done using ABI3130*xl* Genetic Analyzer.

Microsatellite instability analysis {#S20005}
-----------------------------------

Fragment analyzing (ABI 3130*xl* Genetic Analyzer, Applied Biosystems, Bedford, MA, USA) was done using five microsatellite markers: NR-27, NR-21, NR-24, BAT-25 and BAT-26. The samples were classified as high MSI-high if two or more markers showed instability, or MSI-low when only one marker demonstrated instability ([@CIT0022]).

Immunohistochemical analysis of mismatch repair proteins {#S20006}
--------------------------------------------------------

Immunohistochemical staining for MLH1, MSH2 and MSH6 proteins was done as previously described method ([@CIT0023]). Patients with at least one abnormal above factors were considered in abnormal MMRP group.

Statistical analysis {#S20007}
--------------------

SPSS13 software (chi^2^ test and ANOVA) was used to evaluate the association of *p53* nucleotide alterations and clinicopathological findings, MSI and IHC. For all tests the significance level was set at 5%.

Results {#S0008}
=======

Histologically confirmed 97 samples of gastritis lesion were included in the study, 41 male (42.3%, mean age: 44.5 ±17.7) and 56 female (57.7%, mean age: 42.6 ±15.6) in the age range of 15-83 years (43.41±16.48) ([Table 2](#T0002){ref-type="table"}).

###### 

Pathological grading of gastritis lesions according to the update Sydney classification

  Pathology         N    Mean age   Standard Deviation
  ----------------- ---- ---------- --------------------
  Moderate active   33   41.5758    15.25211
  Moderate          39   42.0769    17.33324
  Severe active     21   45.5714    16.05482
  Severe            4    60.2500    14.77329
  Total             97   43.4124    16.48342

Nucleotide changes were seen in exon and intron regions as follows: codons 9, 36, 47, 72, 146, 213, 244, 245, 248, 257, IVS2 + 38 C \> G (rs1642785), IVS3 + 40-41ins16 (*p53*INS3: rs17878362), IVS3-29C \> A (rs17883323), IVS6 + 31A \> G (rs34949160), IVS7 + 72C \> T (rs12947788), IVS7 + 92T \> G (rs12951053).

There were some associations between intron and exon polymorphisms: codon 72 and IVS2 + 38 (p \<0.001), codon 72 and *p53*INS3 (p \<0.001), codon 72 and IVS3-29 (p 0.028), codon 72 and IVS6 + 31 (p 0.05) ([Table 3](#T0003){ref-type="table"}), codon 36 and IVS2 + 38 (p 0.015), codon 245 and IVS2 + 38 (p \<0.001), codon 146 and IVS7 + 72 (p 0.043) ([Table 4](#T0004){ref-type="table"}).

###### 

Statistical correlation between codon 72 and intron variations of p53 gene in gastritis lesion. The number in parentheses shows percentages.

                               IVS2 + 38   IVS3-29    IVS6 + 31   Insertion                                                      
  -------------- ------------- ----------- ---------- ----------- ----------- --------- ---------- -------- --------- ---------- ----------
  **Codon 72**   **CC**        8(57.1)     5(35.7)    1(7.1)      11(78.6)    3(21.4)   13(92.9)   1(7.1)   5(35.7)   4(28.6)    5(35.7)
                 **CG**        0           45(95.7)   2(4.3)      43(91.5)    4(8.5)    47(100)    0        1(2.1)    27(57.4)   19(40.4)
                 **GG**        0           4(11.1)    32(88.9)    36(100)     0         36(100)    0        1(2.8)    32(88.9)   3(8.3)
                 **P value**   \< 0.001    0.028      0.05        \< 0.001                                                       

###### 

Correlation between some exon and intron polymorphisms of p53 gene in gastritis lesion

                        Codon 36    
  ----------- --------- ----------- ---------
  IVS2 + 38             GG          GA
              CC        6(6.5)      2(40)
              CG        51(55.4)    3(60)
              GG        35(38.1)    0
              P value   0.015       
                        Codon 245   
                                    
  IVS2 + 38             GG          GT
              CC        5(5.7)      3(60)
              CG        50(56.8)    1(20)
              GG        33(37.5)    1(20)
              P value   \< 0.001    
                        Codon 146   
                                    
  IVS7 + 72             GG          GC
              CC        77(88.5)    4(57.1)
              CT        9(10.5)     3(42.9)
              P value   0.043       

In the next level, we analyzed the correlation between these associated SNPs with clinicopathological aspects (see the next sections). For details of exon and intron alterations and their correlation with clinicopathological aspect please see next references ([@CIT0009], [@CIT0012]).

Gastritis samples had stable microsatellites, but nine patients showing polymorphism with variant allele for NR-21 and one for Bat-25.

Most of patients with stable microsatellites (83.9%) had allele G (CG or GG) at codon72 without p53INS3 while the other patients had NR-21 polymorphism (p 0.013). In addition, all patients with GA and CG at codon 36 / IVS2 + 38 had stable microsatellites (p= 0.01).

According to specific staining for HP, 87.6% of samples were HP positive. HP infection had no correlation with combined polymorphisms.

There was statistical significant correlation between pathology findings and variation at some polymorphic sites. Most patients (66.7%) with GA/CG and all patients with GA/ CC at codon 36 / IVS2 + 38 had severe gastritis lesion (p 0.022).

Also, most patients (60.4%) with GG/ CG at codon 245/IVS2 + 38 were pathologically active, while most patients (54.5%) with GG / GG were not active (p= 0.034).

There was statistical association between categorized age and polymorphism at codon 72 / IVS3-29 (p 0.017) and codon 72 / IVS6 +31 (p 0.016), So 50% of patients with age less than 45 years have GG and CC at codon 72 / IVS3-29 while 62.2% of patients with age greater than 45 had CG and CC.

In addition, 50% of patients with age less than 45 years had GG and AA genotypes at codon 72 / IVS6 +31 while 64.4% of patients with age more than 45 years had CG and AA genotype (p 0.016). No association was seen between any combination of intron and exon polymorphisms with gender.

Discussion {#S0009}
==========

Gastritis is a precancerous lesion of gastric cancer ([@CIT0024]). According to some reports, about 7300 new cases in Iran (10.5 per 100,000 individuals) are afflicted to gastric cancer annually ([@CIT0011]) with the 5-year survival rate of 23.6% and the median life expectancy of 19.9 months ([@CIT0025]). Therefore, it seems necessary to evaluate and determine molecular events which originate from non-cancerous lesions and lead to malignancy.

Sequential changes in the gastric mucosa may occur over a period of years as a result of exposure to a variety of exogenous and/or endogenous factors which cause genetic alterations such as *p53* mutations and/or select an allele at polymorphic sites. Therefore, early detection of *p53* alterations at the level of precancerous lesions such as gastritis may provide new windows useful for the identifying patients prone to gastric cancer and prevention from gastric cancer development.

According to our findings, variation at codon 72 was statistically associated with *p53*INS3, IVS2 + 38 and IVS3-29. The codon 72 and *p53*IN3 have been extensively studied as putative susceptibility variants in some cancers with inconsistent results. *p53*IN3 is the only intronic polymorphism, that has been associated with an increased risk of several types of cancer ([@CIT0026]). On the other hand, there is some inconsistency about the codon 72 as susceptibility allele for cancer. One possibility is that codon 72 is not the susceptibility allele itself, but instead marks a haplotype with the true susceptibility allele, or that codon 72 is the susceptibility factor and its surrounding SNP (such as *p53*IN3 or other intron/exon SNPs) mark it. The proximity of *p53*INS3 to the codon 72 polymorphism in exon 4 might partly explain the proposed association of this allele with some cancer.

Regarding our findings, it is not surprising to claim that these associated alterations work together during gastritis development.

If either multiple alleles affect susceptibility or codon 72 is the only marker for the actual susceptibility factor is not clear, therefore, it deserves to do a comprehensive study on the multiple SNPs in the different ethnic backgrounds to elucidate this issue. Previous work on gastric cancer and other neoplasia focus on the alterations in the exon regions. Therefore, there is no information about the probable importance and effects of these associated alterations on *p53* functions.

Our findings about the association between some combination of polymorphisms and MSI support the notion of correlation between *p53* and microsatellite status and indicate that some polymorphisms of *p53* gene are correlated with genomic instability. These polymorphisms may affect genomic stability at the nucleotide level through the effect of resultant p53 protein on the repair systems. This is supported by the observation that *p53* is capable of attaching to insertion/deletion loops, the DNA lesions associated with MSI ([@CIT0027]). On the other hands, these variations may lead to the down/ up regulation of MMR system ([@CIT0028]). In this study, we found no MMR defects in relation to *p53* genotypes and microsatellite status, but as we follow MMR system through qualitative IHC, therefore, a quantitative study is recommended to quantify MMR expression.

Regarding current findings concerning to association between the alterations and pathological aspects, it seems possible that GG and CG at codon 245 &IVS2 + 38 has a protective effect against the activity. According to previous work ([@CIT0009], [@CIT0012]), these intron and exon alterations alone had no association with activity. Regarding the severity of gastritis most patients with GA/CG and GA/ CC at codon 36 / IVS2 + 38 had severe gastritis while the patients with other combination of these polymorphisms were diagnosed as moderate gastritis. These findings imply the idea that some functions of a protein and the resultant phenotypes depend on the specific combination of its polymorphisms and also polymorphisms work as a whole not as single "Many hands make light work".

CG / CC genotypes at codon 72 / IVS3-29 and CG / AA genotype at codon72 / IVS6 + 31, were seen predominantly at age greater than 45 years. Therefore, it can be concluded that these combined genotypes have a protective effect against gastritis development while GG / CC and GG / AA genotypes at these sites disposes one to develop gastritis and maybe gastric cancer at the ages less than 45 years, an issue which needs more study.

To our knowledge this is the first comprehensive study on gastritis lesion from view of the size of study and molecular processes which were evaluated such as *p53* exon and intron 2-7, MSI and Immunohistochemistry. In conclusion, the results of this study were shown that some clinicopathological aspects of gastritis lesion are correlated to the co-occurrence of some polymorphisms of *p53* gene. Among them, the combination of codon 72 and IVS2 + 38 with some intron and exon variations had some utmost importance. More studies are needed to delineate the probable molecular events leading to these observations.
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